Marc Ronald Wilkins

Marc Ronald Wilkins

Auto-generated profile, based on publicly available information

Marc Ronald Wilkins

School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, 2052, Australia.

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2006 in Proteomics
Verified
Journal Article
Open access
PDF file
MWMarc R. Wilkins
Marc R. Wilkins
RARon D. Appel
Ron D. Appel
JEJennifer E. Van Eyk
Jennifer E. Van Eyk
MCMaxey C. M. Chung
Maxey C. M. Chung
AGAngelika Görg
Angelika Görg
MDMichael J. Dunn
Michael J. Dunn
In the last ten years, the field of proteomics has expanded at a rapid rate. A range of exciting new technology has been developed and enthusiastically applied to an enormous variety of biological questions. However, the degree of stringency required in proteomic data generation and analysis appears to have been underestimated. As a result, there are likely to be numerous published findings that are of questionable quality, requiring further confirmation and/or validation. This manuscript outlines a number of key issues in proteomic research, including those associated with experimental design, differential display and biomarker discovery, protein identification and analytical incompleteness. In an effort to set a standard that reflects current thinking on the necessary and desirable characteristics of publishable manuscripts in the field, a minimal set of guidelines for proteomics research is then described. These guidelines will serve as a set of criteria which editors of PROTEOMICS will use for assessment of future submissions to the Journal.

16 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SASubash Adhikari
Subash Adhikari
ENEdouard C. Nice
Edouard C. Nice
EDEric W. Deutsch
Eric W. Deutsch
LLLydie Lane
Lydie Lane
GOGilbert S. Omenn
Gilbert S. Omenn
MBMark S. Baker
Mark S. Baker
The Human Proteome Organization (HUPO) launched the Human Proteome Project (HPP) in 2010, creating an international framework for global collaboration, data sharing, quality assurance and enhancing accurate annotation of the genome-encoded proteome. During the subsequent decade, the HPP established collaborations, developed guidelines and metrics, and undertook reanalysis of previously deposited community data, continuously increasing the coverage of the human proteome. On the occasion of the HPP’s tenth anniversary, we here report a 90.4% complete high-stringency human proteome blueprint. This knowledge is essential for discerning molecular processes in health and disease, as we demonstrate by highlighting potential roles the human proteome plays in our understanding, diagnosis and treatment of cancers, cardiovascular and infectious diseases.

17 June 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LLLucia Lorenzi
Lucia Lorenzi
HCHua-Sheng Chiu
Hua-Sheng Chiu
FCFrancisco Avila Cobos
Francisco Avila Cobos
SGStephen Gross
Stephen Gross
Pieter-Jan VoldersPieter-Jan Volders
Pieter-Jan Volders
PMPieter Mestdagh
Pieter Mestdagh

13 May 2019 in Cancers
Verified
Journal Article
Open access
PDF file
BLBrandon Lowe
Brandon Lowe
LMLily A. Maxham
Lily A. Maxham
JHJoshua J. Hamey
Joshua J. Hamey
MWMarc R. Wilkins
Marc R. Wilkins
JPJanet Partridge
Janet Partridge
In this review, we describe the attributes of histone H3 mutants identified in cancer. H3 mutants were first identified in genes encoding H3.3, in pediatric high-grade glioma, and subsequently in chondrosarcomas and giant cell tumors of bone (GCTB) in adolescents. The most heavily studied are the lysine to methionine mutants K27M and K36M, which perturb the target site for specific lysine methyltransferases and dominantly perturb methylation of corresponding lysines in other histone H3 proteins. We discuss recent progress in defining the consequences of these mutations on chromatin, including a newly emerging view of the central importance of the disruption of H3K36 modification in many distinct K to M histone mutant cancers. We also review new work exploring the role of H3.3 G34 mutants identified in pediatric glioma and GCTB. G34 is not itself post-translationally modified, but G34 mutation impinges on the modification of H3K36. Here, we ask if G34R mutation generates a new site for methylation on the histone tail. Finally, we consider evidence indicating that histone mutations might be more widespread in cancer than previously thought, and if the perceived bias towards mutation of H3.3 is real or reflects the biology of tumors in which the histone mutants were first identified.

18 April 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
TBTara K. Bartolec
Tara K. Bartolec
XVXabier Vázquez-Campos
Xabier Vázquez-Campos
ANAlexander Norman
Alexander Norman
CLClement Luong
Clement Luong
MJMarcus Johnson
Marcus Johnson
JLJason K. K. Low
Jason K. K. Low
Significant recent advances in structural biology, particularly in the field of cryoelectron microscopy, have dramatically expanded our ability to create structural models of proteins and protein complexes. However, many proteins remain refractory to these approaches because of their low abundance, low stability, or—in the case of complexes—simply not having yet been analyzed. Here, we demonstrate the power of using cross-linking mass spectrometry (XL-MS) for the high-throughput experimental assessment of the structures of proteins and protein complexes. This included those produced by high-resolution but in vitro experimental data, as well as in silico predictions based on amino acid sequence alone. We present the largest XL-MS dataset to date, describing 28,910 unique residue pairs captured across 4,084 unique human proteins and 2,110 unique protein–protein interactions. We show that models of proteins and their complexes predicted by AlphaFold2, and inspired and corroborated by the XL-MS data, offer opportunities to deeply mine the structural proteome and interactome and reveal mechanisms underlying protein structure and function.

18 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAndre Mu
Andre Mu
WKWilliam P. Klare
William P. Klare
SBSarah L Baines
Sarah L Baines
CPC. N. Ignatius Pang
C. N. Ignatius Pang
RGRomain Guérillot
Romain Guérillot
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
Even in the setting of optimal resuscitation in high-income countries severe sepsis and septic shock have a mortality of 20–40%, with antibiotic resistance dramatically increasing this mortality risk. To develop a reference dataset enabling the identification of common bacterial targets for therapeutic intervention, we applied a standardized genomic, transcriptomic, proteomic and metabolomic technological framework to multiple clinical isolates of four sepsis-causing pathogens: Escherichia coli, Klebsiella pneumoniae species complex, Staphylococcus aureus and Streptococcus pyogenes. Exposure to human serum generated a sepsis molecular signature containing global increases in fatty acid and lipid biosynthesis and metabolism, consistent with cell envelope remodelling and nutrient adaptation for osmoprotection. In addition, acquisition of cholesterol was identified across the bacterial species. This detailed reference dataset has been established as an open resource to support discovery and translational research.